Tate, S.; Nishikimi, K.; Matsuoka, A.; Otsuka, S.; Shiko, Y.; Ozawa, Y.; Kawasaki, Y.; Shozu, M.
Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. Cancers 2021, 13, 3177.
https://doi.org/10.3390/cancers13133177
AMA Style
Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shiko Y, Ozawa Y, Kawasaki Y, Shozu M.
Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. Cancers. 2021; 13(13):3177.
https://doi.org/10.3390/cancers13133177
Chicago/Turabian Style
Tate, Shinichi, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, and Makio Shozu.
2021. "Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma" Cancers 13, no. 13: 3177.
https://doi.org/10.3390/cancers13133177
APA Style
Tate, S., Nishikimi, K., Matsuoka, A., Otsuka, S., Shiko, Y., Ozawa, Y., Kawasaki, Y., & Shozu, M.
(2021). Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. Cancers, 13(13), 3177.
https://doi.org/10.3390/cancers13133177